Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | TP53 | P04637 | 12/20 | 0.54 |
| ▸ | LMNA | P02545 | 8/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21545406 | 1.00 | HTR2B (0.69) | HTR2BMAPTTP53LMNACASP6 | |
| SCHEMBL21545547 | 0.94 | HTR2B (0.66) | HTR2BMAPTTP53LMNACASP6 | |
| SCHEMBL21947547 | 0.93 | MAPT (0.60) | HTR2BMAPTTP53LMNAPOLB | |
| SCHEMBL21569279 | 0.93 | MAPT (0.60) | HTR2BMAPTTP53LMNAPOLB | |
| SCHEMBL21569234 | 0.93 | HTR2B (0.58) | HTR2BMAPTTP53LMNACASP6 | |
| SCHEMBL17109118 | 0.91 | HTR2B (0.76) | HTR2BMAPTTP53LMNACASP6 | |
| SCHEMBL21569343 | 0.91 | HTR2B (0.66) | HTR2BMAPTTP53LMNACASP6 | |
| SCHEMBL21545661 | 0.90 | HTR2B (0.56) | HTR2BMAPTTP53LMNAPOLB | |
| SCHEMBL21545662 | 0.90 | HTR2B (0.56) | HTR2BMAPTTP53LMNAPOLB | |
| SCHEMBL17115724 | 0.90 | HTR2B (0.75) | HTR2BMAPTTP53LMNACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | HTR2B 1/4885MAPT 4615/4885TP53 3645/4885 |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | HTR2B, HTR3B, HTR1A | HTR2B 1/4885MAPT 4615/4885TP53 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.